Equities research analysts expect that Odonate Therapeutics Inc (NASDAQ:ODT) will post earnings per share of ($1.17) for the current quarter, Zacks Investment Research reports. Zero analysts have issued estimates for Odonate Therapeutics’ earnings. Odonate Therapeutics posted earnings of ($0.79) per share during the same quarter last year, which would suggest a negative year-over-year growth rate of 48.1%. The company is expected to report its next quarterly earnings results on Monday, July 29th.

According to Zacks, analysts expect that Odonate Therapeutics will report full-year earnings of ($4.44) per share for the current year, with EPS estimates ranging from ($4.75) to ($4.12). For the next financial year, analysts anticipate that the company will report earnings of ($4.39) per share, with EPS estimates ranging from ($4.60) to ($4.17). Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of sell-side research analysts that cover Odonate Therapeutics.

Odonate Therapeutics (NASDAQ:ODT) last issued its quarterly earnings results on Thursday, April 25th. The company reported ($1.16) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.24) by $0.08.

A number of research analysts recently issued reports on ODT shares. Cowen reiterated a “buy” rating on shares of Odonate Therapeutics in a research note on Monday, June 3rd. ValuEngine lowered Odonate Therapeutics from a “buy” rating to a “hold” rating in a research report on Thursday, April 18th. Finally, Zacks Investment Research lowered Odonate Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, March 2nd.

In other news, CEO Kevin C. Tang purchased 93,692 shares of the business’s stock in a transaction dated Wednesday, June 5th. The stock was bought at an average cost of $24.92 per share, with a total value of $2,334,804.64. The acquisition was disclosed in a document filed with the SEC, which is available through this link. Also, CEO Kevin C. Tang purchased 76,308 shares of the business’s stock in a transaction dated Friday, June 7th. The shares were purchased at an average cost of $27.36 per share, with a total value of $2,087,786.88. The disclosure for this purchase can be found here. 49.00% of the stock is owned by company insiders.

Institutional investors and hedge funds have recently bought and sold shares of the company. BNP Paribas Arbitrage SA raised its stake in shares of Odonate Therapeutics by 1,187.5% in the 1st quarter. BNP Paribas Arbitrage SA now owns 1,442 shares of the company’s stock valued at $32,000 after acquiring an additional 1,330 shares in the last quarter. Menta Capital LLC bought a new position in shares of Odonate Therapeutics in the 4th quarter valued at approximately $187,000. TD Asset Management Inc. raised its stake in shares of Odonate Therapeutics by 60.8% in the 4th quarter. TD Asset Management Inc. now owns 17,962 shares of the company’s stock valued at $253,000 after acquiring an additional 6,793 shares in the last quarter. Renaissance Technologies LLC raised its stake in shares of Odonate Therapeutics by 52.0% in the 1st quarter. Renaissance Technologies LLC now owns 19,300 shares of the company’s stock valued at $427,000 after acquiring an additional 6,600 shares in the last quarter. Finally, JPMorgan Chase & Co. raised its stake in shares of Odonate Therapeutics by 177.9% in the 1st quarter. JPMorgan Chase & Co. now owns 40,058 shares of the company’s stock valued at $886,000 after acquiring an additional 25,641 shares in the last quarter. 91.48% of the stock is owned by institutional investors.

Odonate Therapeutics stock traded up $0.13 during trading on Wednesday, reaching $24.65. The stock had a trading volume of 117,800 shares, compared to its average volume of 59,903. Odonate Therapeutics has a 52-week low of $11.54 and a 52-week high of $28.46. The company has a market capitalization of $655.91 million, a P/E ratio of -6.77 and a beta of 0.60.

About Odonate Therapeutics

Odonate Therapeutics, Inc, a pharmaceutical company, develops therapeutics for the treatment of cancer. It is developing tesetaxel, an orally administered chemotherapy agent, which is in Phase III clinical study for patients with locally advanced or metastatic breast cancer. The company was founded in 2013 and is based in San Diego, California.

Featured Story: What is a trade deficit?

Get a free copy of the Zacks research report on Odonate Therapeutics (ODT)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Odonate Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Odonate Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.